Second ovarian drug

FIRST CLICK HERE  AND READ OUR OVERVIEW

The UK’s National Institute for Clinical Excellence (NICE) has added PLDH to the approved topotecan, as a second line drug for use with advanced ovarian cancers.

NICE have suggested that PLDH has a simpler administration schedule.

CancerAcitve Logo
Subscribe (Free e-Newsletter)

Join Our
Newsletter

Join Our Newsletter Signup today for free and be the first to get notified on new updates.